|
|
 |
|
 |
|
No. |
Name |
Postion
/ Subject |
1 |
Dong-Seok Yim |
Associate Professorr,
The Catholic University, Korea
Looking
into the population analysis of densely sampled
pharmacokinetic data |
2 |
Young-Ran Yoon |
Assistant Professor,
Kyungpook National University, Korea
PK/PD
modeling for fexofenadine with polysomsography
|
3 |
Kyung-Sang Yu |
Assistant Professor,
Seoul National University, Korea
Application
of PK-PD modeling and clinical trial simulation
in drug development: Example of PET imaging
biomarkers |
4 |
Kyun-Seop Bae |
Assistant Professor,
University of Ulsan, Korea
Population
PK-PD Modeling of Clopidogrel |
5 |
Suk-Jae Chung |
Associate Professor,
Seoul National University, Korea
Functional
Implication of Transporters on Pharmacokinetics
during Nitrosative Stress |
|
| |
Profiles |
Dong-Seok Yim
|
Biography
He is currently working as associate professor
at the Dept. of Pharmacology of The Catholic
University of Korea and chair of the Dept.
of Clinical Pharmacology of Kangnam St. Mary’s
Hospital in Seoul. After graduating from Seoul
National University (SNU), College of Medicine
in 1992 (M.D.), he got four years’ training
of clinical pharmacology at the graduate school
of SNU Ph.D.). His paper on the pop. PK of
phenytoin in Korean patients then was the
first study which used NONMEM software in
Korea. After serving at Korea FDA for three
years to fulfill military duty, he got two
years’ international fellowship at the Center
for Drug Development Science (CDDS) of Georgetown
University (Director: Carl Peck). During the
fellowship, he also worked as a visiting scientist
at CDER, FDA. A population PK-PD project on
glucose-HbA1c model and a simulation to compare
the conventional and individual bioequivalence
study data were projects led by him at CDER.
Back in Korea since 2005, he has been leading
his PK-PD lab of Clinical Research Cooperating
Center (CRCC) of Catholic Univ., one of the
regional clinical trial centers supported
by Korean government.
A
brief description of the presentation
He will briefly review the implication of
mixed effect model approach in the data rich
environment and share his experience obtained
in the course of modeling with densely sampled
pharmacokinetic data from several tens of
subjects.
|
Young-Ran Yoon
|
Biography
Dr. Yoon is an Assistant Professor of Clinical
Pharmacology at the Department of Molecular
Medicine of the Kyungpook National University(KNU)
School of Medicine, and is also working at
the Clinical Trial Center of KNU Hospital
in Daegu, Korea. After graduating from the
College of Medicine, Inje University, she
had studied and got her Ph.D. degree from
Seoul National University in 1998. She worked
on various clinical pharmacology research
projects at Inje University until 2003. She
had got her post-doctoral training in the
Division of Clinical Pharmacology, University
of California at San Francisco (mentors: Dr.
Neal L Benowitz and Dr. Davide Verotta), from
January, 2004 to June, 2005, and at present,
she is working in KNU.
She is interested in drug metabolism and metabolomics,
pharmacogenomics, and early phase clinical
trials.
A
brief description of the presentation
This presentation is about the differences
in nocturnal polysomnographic characteristics
between two drugs of different generations
of anti-histaminergics, fexofenadine and chloropheniramine.
And the pharmacokinetics of fexofenadine was
modeled with its sleep electroencephalogram(EEG)
information.
|
Kyung-Sang Yu |
Biography
Dr. Yu is currently an Assistant Professor
of Clinical Pharmacology at the College of
Medicine, Seoul National University (SNU),
and is also affiliated to the Clinical Trial
Center of Seoul National University Hospital
(SNUH). After graduating from the College
of Medicine, SNU, he has taken an internship
at SNUH, and went on to be trained in the
clinical pharmacology residency program there.
He has received his Ph.D. from this university
in 2000, and has been involved in many clinical
pharmacology study projects.
He is interested in various fields related
to early phase clinical trials and pharmacogenomic
research.
A brief description
of the presentation
This talk will focus on a case of a novel
antipsychotic agent, in which serial PET images
in healthy volunteers were used to estimate
brain D2 receptor occupancies. Using this
information combined with blood concentrations,
a PK-PD model was developed, and clinical
trial simulation was conducted in order to
optimize designs for further trials in patients.
|
Kyun-Seop Bae |
Biography
Dr. Bae is an assistant professor at the Department
of Clinical Pharmacology and Therapeutics
of Asan Medical Center and University of Ulsan,
Korea. He graduated from Seoul National University
College of Medicine in 1994. After internship
and residency of clinical pharmacology at
Seoul National University Hospital, he joined
Asan Medical Center in 2002. He conducted
more than 20 phase 1 clinical trials as a
principal investigator at Asan Medical Center
since 2003. He also actively involved in developing
clinical research center at Asan Medical Center.
His academic interests are pharmacometrics
and developing software for clinical pharmacology.
A brief description of the presentation
Clopidogrel is an inhibitor of ADP induced
platelet aggregation and widely used for ischemic
heart disease and ischemic stroke. We measured
parent and metabolite of clopidorel, and tested
platelet aggregation function in 70 healthy
volunteers. We also explored the effect of
CYP enzyme geontype and ADP receptor genotype.
|
Suk-Jae Chung |
Biography
Dr. Suk-Jae Chung is currently an associate
professor of Pharmaceutical Sciences at the
College of Pharmacy, Seoul National University.
After graduating from Seoul National University,
College of Pharmacy in 1984
(B.S.) and 1986 (M.S.), he received his Ph.
D. degree from the Department of Pharmaceutics,
State University of New York at Buffalo (1992)
under the guidance of Professor Ho-Leung Fung.
Dr. Chung got his post-doctoral training in
the Department of Pharmaceutical Sciences,
University of California at San Francisco
(supervisor: Professor Kathleen Giacomini).
Dr. Chung’s primary research interests include
the functional implication of transporter,
OAT3 and MDR, in the alteration of pharmacokinetics
during disease states associated with nitrosative
stress.
A brief description
of the presentation
In this presentation, two lines of investigation
will be presented for alterations in functional
activities of carriers expressed in barriers
of between the systemic circulation and the
brain, and the resulting pharmacokinetics
by nitrogen oxide (NOx) forms.
|
|
|
| |
|
|
|
|
